ADMA Biologics Company Profile (NASDAQ:ADMA)

About ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics logoADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADMA
  • CUSIP: N/A
  • Web: www.admabiologics.com
Capitalization:
  • Market Cap: $52.32 million
  • Outstanding Shares: 12,886,000
Average Prices:
  • 50 Day Moving Avg: $3.79
  • 200 Day Moving Avg: $4.62
  • 52 Week Range: $2.93 - $8.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.14
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.17 million
  • Price / Sales: 4.68
  • Book Value: ($0.83) per share
  • Price / Book: -4.89
Profitability:
  • EBIDTA: ($18,640,000.00)
  • Net Margins: -191.99%
  • Return on Equity: -6,405.90%
  • Return on Assets: -85.33%
Debt:
  • Debt-to-Equity Ratio: -1.01%
  • Current Ratio: 1.21%
  • Quick Ratio: 0.80%
Misc:
  • Average Volume: 32,916 shs.
  • Beta: 2.56
  • Short Ratio: 2.26
 

Frequently Asked Questions for ADMA Biologics (NASDAQ:ADMA)

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) announced its quarterly earnings results on Friday, May, 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.23. The firm had revenue of $2.63 million for the quarter, compared to analyst estimates of $3.35 million. ADMA Biologics had a negative net margin of 191.99% and a negative return on equity of 6,405.90%. View ADMA Biologics' Earnings History.

When will ADMA Biologics make its next earnings announcement?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Thursday, August, 10th 2017. View Earnings Estimates for ADMA Biologics.

Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?

2 brokers have issued 1-year price objectives for ADMA Biologics' shares. Their predictions range from $13.00 to $13.00. On average, they anticipate ADMA Biologics' share price to reach $13.00 in the next year. View Analyst Ratings for ADMA Biologics.

Who are some of ADMA Biologics' key competitors?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:

  • Steven A. Elms, Chairman of the Board
  • Adam S. Grossman, President, Chief Executive Officer, Director
  • Jerrold B. Grossman D.P.S, Vice Chairman of the Board
  • Brian Lenz, Chief Financial Officer
  • James Mond M.D., Ph.D., Chief Scientific and Medical Officer
  • Bernhard R. M. Ehmer, Director
  • Bryant E. Fong, Independent Director
  • Dov A. Goldstein M.D., Independent Director
  • Lawrence P. Guiheen, Independent Director
  • Eric I. Richman, Independent Director

Who owns ADMA Biologics stock?

ADMA Biologics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BIOTEST AG (25.00%), Aisling Capital LLC (0.00%), Biomark Capital Management Co. LLC (0.00%), Broadfin Capital LLC (7.98%), Perceptive Advisors LLC (5.60%) and FMR LLC (0.00%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.

Who sold ADMA Biologics stock? Who is selling ADMA Biologics stock?

ADMA Biologics' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Weiss Multi Strategy Advisers LLC and FMR LLC. View Insider Buying and Selling for ADMA Biologics.

Who bought ADMA Biologics stock? Who is buying ADMA Biologics stock?

ADMA Biologics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.

How do I buy ADMA Biologics stock?

Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA Biologics stock can currently be purchased for approximately $4.06.


MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.00 (220.20% upside)

Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/7/2017Maxim GroupSet Price TargetBuy$13.00LowView Rating Details
8/1/2016Raymond James Financial, Inc.DowngradeStrong-Buy -> Market PerformN/AView Rating Details
(Data available from 6/27/2015 forward)

Earnings

Earnings History for ADMA Biologics (NASDAQ:ADMA)
Earnings by Quarter for ADMA Biologics (NASDAQ:ADMA)
Earnings History by Quarter for ADMA Biologics (NASDAQ ADMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2017        
5/12/2017Q1 2017($0.28)($0.51)$3.35 million$2.63 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.42)($0.34)$2.32 million$2.94 millionViewN/AView Earnings Details
8/12/2016Q2($0.39)($0.50)$2.35 million$2.27 millionViewN/AView Earnings Details
5/13/2016Q1($0.37)($0.43)$2.48 million$2.12 millionViewN/AView Earnings Details
11/10/2015Q315($0.39)($0.48)$1.50 million$1.85 millionViewN/AView Earnings Details
8/11/2015Q215($0.32)($0.37)$1.50 million$1.30 millionViewN/AView Earnings Details
5/12/2015Q115($0.32)($0.37)$1.50 million$1.50 millionViewN/AView Earnings Details
3/9/2015Q4 2014($0.38)($0.38)$1.52 million$1.41 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.37)($0.36)$1.37 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.30)($0.30)($0.30)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ADMA Biologics (NASDAQ:ADMA)
Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 71.65%
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/3/2016Adam S GrossmanCEOBuy200,000$6.50$1,300,000.00View SEC Filing  
5/3/2016Brian LenzCFOBuy2,500$6.50$16,250.00View SEC Filing  
5/3/2016James MondCMOBuy770$6.50$5,005.00View SEC Filing  
5/3/2016Jerrold B GrossmanDirectorBuy45,769$6.50$297,498.50View SEC Filing  
12/8/2015Adam S. GrossmanCEOBuy500$9.00$4,500.00View SEC Filing  
12/7/2015Jerrold B GrossmanDirectorBuy500$9.01$4,505.00View SEC Filing  
12/2/2015Adam S GrossmanCEOBuy2,250$9.15$20,587.50View SEC Filing  
12/2/2015Brian LenzCFOBuy1,000$9.15$9,150.00View SEC Filing  
12/2/2015Jerrold B GrossmanDirectorBuy6,000$9.16$54,960.00View SEC Filing  
12/1/2015Adam S GrossmanCEOBuy1,800$9.17$16,506.00View SEC Filing  
11/25/2015Adam S GrossmanCEOBuy1,800$9.18$16,524.00View SEC Filing  
11/20/2015Adam S GrossmanCEOBuy3,861$9.21$35,559.81View SEC Filing  
3/19/2015Adam S GrossmanCEOBuy2,000$8.50$17,000.00View SEC Filing  
3/17/2015Adam S GrossmanCEOBuy5,500$7.98$43,890.00View SEC Filing  
3/17/2015Jerrold B GrossmanDirectorBuy500$8.01$4,005.00View SEC Filing  
3/16/2015Adam S GrossmanCEOBuy8,800$8.03$70,664.00View SEC Filing  
3/16/2015James MondCMOBuy1,250$8.02$10,025.00View SEC Filing  
3/16/2015Lawrence P GuiheenDirectorBuy1,000$7.96$7,960.00View SEC Filing  
3/13/2015Eric I RichmanDirectorBuy3,500$7.88$27,580.00View SEC Filing  
9/12/2014Adam S GrossmanCEOBuy4,300$9.57$41,151.00View SEC Filing  
8/22/2014Adam S GrossmanCEOBuy1,000$9.50$9,500.00View SEC Filing  
8/14/2014Adam S GrossmanCEOBuy2,100$9.77$20,517.00View SEC Filing  
6/18/2014Adam S GrossmanCEOBuy1,875$9.59$17,981.25View SEC Filing  
5/22/2014Adam S GrossmanCEOBuy4,226$8.15$34,441.90View SEC Filing  
5/15/2014Adam S GrossmanCEOBuy13,400$7.50$100,500.00View SEC Filing  
5/14/2014Brian LenzCFOBuy1,000$7.50$7,500.00View SEC Filing  
5/14/2014James MondCMOBuy1,315$7.60$9,994.00View SEC Filing  
12/10/2013Jerrold B GrossmanDirectorBuy3,650$7.30$26,645.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ADMA Biologics (NASDAQ:ADMA)
Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
Source:
DateHeadline
finance.yahoo.com logoADMA Biologics Provides Corporate Timeline and Activities Update to Stockholders
finance.yahoo.com - June 27 at 3:24 PM
reuters.com logoBRIEF-Adma Biologics says approved 5 pct increases in annual cash bonuses to CEO, CFO among others
www.reuters.com - June 9 at 8:26 PM
seekingalpha.com logoADMA Biologics (ADMA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 8:26 PM
americanbankingnews.com logoZacks: ADMA Biologics Inc (ADMA) Given $10.50 Average Target Price by Brokerages
www.americanbankingnews.com - June 8 at 8:50 AM
americanbankingnews.com logoADMA Biologics Inc (ADMA) Given a $13.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - June 7 at 7:18 PM
reuters.com logoBRIEF-Biotest ‍sells US therapy business to Adma Biologics, Inc.
www.reuters.com - June 7 at 3:24 PM
finance.yahoo.com logoADMA Biologics Completes Acquisition of Biotest’s Therapy Business Unit Assets
finance.yahoo.com - June 6 at 8:33 PM
finance.yahoo.com logoETFs with exposure to ADMA Biologics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 6:41 PM
americanbankingnews.com logoZacks: Brokerages Anticipate ADMA Biologics Inc (ADMA) Will Announce Quarterly Sales of $3.32 Million
www.americanbankingnews.com - June 4 at 7:54 AM
americanbankingnews.com logoADMA Biologics Inc (ADMA) Expected to Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - June 2 at 6:24 PM
finance.yahoo.com logoADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 4:15 PM
finance.yahoo.com logoADMA Biologics to Present at Jefferies 2017 Healthcare Conference
finance.yahoo.com - May 25 at 8:38 PM
finance.yahoo.com logoADMA: 1Q:17 Results and Biotest Acquisition: Valuation Implications
finance.yahoo.com - May 19 at 8:19 PM
americanbankingnews.com logoADMA Biologics Inc to Post Q2 2017 Earnings of ($0.30) Per Share, Zacks Investment Research Forecasts (ADMA)
www.americanbankingnews.com - May 18 at 8:42 AM
americanbankingnews.com logoADMA Biologics Inc (ADMA) Announces Earnings Results
www.americanbankingnews.com - May 15 at 10:58 AM
reuters.com logoBRIEF-ADMA Biologics Q1 loss per share $0.51
www.reuters.com - May 13 at 3:23 PM
finance.yahoo.com logoADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 12 at 8:54 PM
finance.yahoo.com logoAdma Biologics reports 1Q loss
finance.yahoo.com - May 12 at 8:54 PM
americanbankingnews.com logoADMA Biologics Inc (ADMA) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 9 at 7:00 AM
americanbankingnews.com logoADMA Biologics (ADMA) Receiving Positive News Coverage, Report Finds
www.americanbankingnews.com - May 4 at 7:54 AM
americanbankingnews.com logoADMA Biologics (ADMA) Earns Daily News Sentiment Rating of 0.37
www.americanbankingnews.com - April 26 at 2:08 PM
americanbankingnews.com logoADMA Biologics (ADMA) Receiving Very Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 7:38 AM
finance.yahoo.com logoETFs with exposure to ADMA Biologics, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 3:21 PM
americanbankingnews.com logoADMA Biologics (ADMA) Receives Coverage Optimism Rating of 0.33
www.americanbankingnews.com - April 15 at 8:46 AM
finance.yahoo.com logoETFs with exposure to ADMA Biologics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 8:21 PM
americanbankingnews.com logoShort Interest in ADMA Biologics Inc (ADMA) Rises By 13.6%
www.americanbankingnews.com - April 6 at 11:51 AM
uk.finance.yahoo.com logoBiotest AG: Discussions regarding possible business combination
uk.finance.yahoo.com - March 29 at 8:27 PM
prnewswire.com logoShareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA - PR Newswire (press release)
www.prnewswire.com - March 28 at 8:02 AM
finance.yahoo.com logoShareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA
finance.yahoo.com - March 28 at 8:02 AM
finance.yahoo.com logoADMA BIOLOGICS, INC. Financials
finance.yahoo.com - March 2 at 3:30 PM
biz.yahoo.com logoADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - February 24 at 6:19 PM
finance.yahoo.com logoADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones
finance.yahoo.com - February 24 at 6:19 PM
biz.yahoo.com logoADMA BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 18 at 7:49 AM
streetinsider.com logoForm 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: LENZ BRIAN - StreetInsider.com
www.streetinsider.com - February 17 at 9:41 AM
streetinsider.com logoForm 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: Guiheen Lawrence P. - StreetInsider.com
www.streetinsider.com - February 17 at 9:41 AM
prnewswire.com logoBlood Plasma Market 2017-2021 Key Regions Competitive Analysis
www.prnewswire.com - January 27 at 9:45 PM
streetinsider.com logoADMA Biologics (ADMA) to Acquire Assets from Biotest Pharmaceuticals
www.streetinsider.com - January 25 at 1:43 AM
finanznachrichten.de logoDGAP-Adhoc: Biotest AG: Biotest verkauft US-Therapiegeschäft an ... - FinanzNachrichten.de
www.finanznachrichten.de - January 24 at 1:25 AM
finance.yahoo.com logoADMA Biologics upgraded by Maxim Group
finance.yahoo.com - January 23 at 8:24 PM
biz.yahoo.com logoADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu
biz.yahoo.com - January 23 at 8:24 PM

Social

Chart

ADMA Biologics (ADMA) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by MarketBeat.com Staff